Observational studyMedicine2026
Revealing the cuproptosis-lncRNA nexus in gastric cancer: A multicohort observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
To establish a cuproptosis-related lncRNA signature and evaluate its prognostic value and potential immunological relevance in gastric cancer (GC). Transcriptomic data from the cancer genome atlas and gene expression omnibus were analyzed using Pearson correlation and least absolute shrinkage and selection operator Cox regression to construct the prognostic model. Model performance was assessed by Kaplan-Meier analysis, time-dependent receiver operating characteristic curves, and decision curve analysis. An mRNA-based RS score was further validated in Gene Expression Omnibus datasets and the IMvigor210 cohort. Expression of 2 key long noncoding RNAs (AC245041.1 and LINC01614) was confirmed by qRT-PCR in an independent GC cohort. A 25-lncRNA cuproptosis-related signature effectively stratified patients into high- and low-risk groups, with the high-risk group showing significantly poorer survival. The model outperformed conventional clinical variables. Functional enrichment suggested involvement of immune regulation and mitochondrial pathways related to cuproptosis, and the low-risk group displayed a more immunologically active profile. The RS score showed consistent predictive performance across external cohorts, and qRT-PCR validated the prognostic relevance of AC245041.1 and LINC01614. This cuproptosis-related lncRNA signature demonstrates potential as a prognostic indicator and may provide insights into immunotherapy relevance, offering a promising direction for personalized GC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.